Nanobiotix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.07.23	Voting Rights and Shares Capital of the Company (GlobeNewswire)
19.07.23	NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers (GlobeNewswire)
10.07.23	NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3 (GlobeNewswire)
08.06.23	Voting Rights and Shares Capital of the Company (GlobeNewswire)
17.05.23	NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update (GlobeNewswire)
05.05.23	NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company (GlobeNewswire)
25.04.23	NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
17.04.23	NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 (GlobeNewswire)
11.04.23	Voting Rights and Shares Capital of the Company (GlobeNewswire)
27.03.23	Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call (GlobeNewswire)
14.03.23	Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire)
14.02.23	Voting Rights and Shares Capital of the Company (GlobeNewswire)
10.10.22	Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
28.09.22	Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 (Businesswire)
22.09.22	Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022 (Businesswire)
21.09.22	Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy (Businesswire)
12.09.22	Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024 (Businesswire)
08.09.22	Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
07.09.22	NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer (Businesswire)
06.09.22	NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences (Businesswire)
31.08.22	Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022 (Businesswire)
09.08.22	NANOBIOTIX: Voting Rights and Shares Capital of the Company (Businesswire)
13.07.22	Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont (Businesswire)
08.07.22	Nanobiotix: Voting Rights and Shares Capital of the Company (Businesswire)
09.06.22	NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
05.06.22	NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications (Businesswire)
02.06.22	NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 (Businesswire)
19.05.22	CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update (Businesswire)
18.05.22	NANOBIOTIX Provides First Quarter Operational and Financial Update (Businesswire)
17.05.22	NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022 (Businesswire)
11.05.22	NANOBIOTIX to Participate in Two Upcoming Investor Conferences (Businesswire)
10.05.22	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
04.05.22	NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022 (Businesswire)
02.05.22	New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting (Businesswire)
11.04.22	NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3 (Businesswire)
08.04.22	NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F (Businesswire)
07.04.22	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
30.03.22	NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results (Businesswire)
16.03.22	NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022 (Businesswire)
08.03.22	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
10.02.22	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
09.02.22	Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer (Businesswire)
26.01.22	NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 (Businesswire)
11.01.22	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
10.01.22	NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets (Businesswire)
05.01.22	NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer (Businesswire)
04.01.22	Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 (Businesswire)
08.12.21	Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
30.06.21	NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer (Businesswire)
01.06.21	NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nanobiotix SA

Aktien Top/Flop

Meistgelesene Nachrichten